(EXPO) Exponent - Ratings and Ratios
Engineering Consulting, Scientific Analysis, Regulatory Advice
EXPO EPS (Earnings per Share)
EXPO Revenue
Description: EXPO Exponent
Exponent Inc (NASDAQ:EXPO) is a science and engineering consulting firm that provides a wide range of services across two main segments: Engineering and Other Scientific, and Environmental and Health. The companys expertise spans multiple areas, including biomechanics, data sciences, electrical engineering, and environmental sciences, among others.
The companys diverse service offerings enable it to cater to various industries, such as chemical, construction, consumer products, energy, and life sciences. Exponents clients include government agencies, insurance companies, manufacturers, and technology firms. With a history dating back to 1967, the company has established itself as a reputable player in the research and consulting services sector.
From a financial perspective, Exponents revenue growth and profitability are key performance indicators (KPIs) to monitor. The companys return on equity (RoE) of 25.33% indicates a strong ability to generate profits from shareholder equity. Additionally, the price-to-earnings (P/E) ratio of 34.85 and forward P/E of 36.50 suggest that investors have high expectations for the companys future earnings growth.
To further evaluate Exponents performance, other relevant KPIs could include revenue growth rate, operating margin, and employee utilization rates. The companys ability to attract and retain top talent in the science and engineering fields is also crucial to its success. Furthermore, Exponents competitive positioning within the research and consulting services industry, as well as its ability to adapt to changing regulatory environments, are important factors to consider when assessing its long-term prospects.
EXPO Stock Overview
| Market Cap in USD | 3,633m |
| Sub-Industry | Research & Consulting Services |
| IPO / Inception | 1990-08-17 |
EXPO Stock Ratings
| Growth Rating | -54.8% |
| Fundamental | 79.3% |
| Dividend Rating | 61.5% |
| Return 12m vs S&P 500 | -43.3% |
| Analyst Rating | 3.67 of 5 |
EXPO Dividends
| Dividend Yield 12m | 1.55% |
| Yield on Cost 5y | 1.62% |
| Annual Growth 5y | 8.06% |
| Payout Consistency | 100.0% |
| Payout Ratio | 46.8% |
EXPO Growth Ratios
| Growth Correlation 3m | -70.1% |
| Growth Correlation 12m | -97.7% |
| Growth Correlation 5y | -17.1% |
| CAGR 5y | -6.90% |
| CAGR/Max DD 3y | -0.17 |
| CAGR/Mean DD 3y | -0.38 |
| Sharpe Ratio 12m | -1.88 |
| Alpha | -36.41 |
| Beta | 0.004 |
| Volatility | 26.83% |
| Current Volume | 254.3k |
| Average Volume 20d | 479.9k |
| Stop Loss | 67.9 (-3.1%) |
| Signal | -0.49 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (102.8m TTM) > 0 and > 6% of Revenue (6% = 33.6m TTM) |
| FCFTA 0.21 (>2.0%) and ΔFCFTA 0.55pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 51.86% (prev 46.90%; Δ 4.96pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.22 (>3.0%) and CFO 129.3m > Net Income 102.8m (YES >=105%, WARN >=100%) |
| Net Debt (-151.5m) to EBITDA (146.7m) ratio: -1.03 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.15 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (51.6m) change vs 12m ago 0.14% (target <= -2.0% for YES) |
| Gross Margin 56.74% (prev 28.39%; Δ 28.36pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 87.08% (prev 78.02%; Δ 9.06pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' 10.46
| (A) 0.50 = (Total Current Assets 425.7m - Total Current Liabilities 135.0m) / Total Assets 578.2m |
| (B) 1.12 = Retained Earnings (Balance) 646.0m / Total Assets 578.2m |
| warn (B) unusual magnitude: 1.12 — check mapping/units |
| (C) 0.22 = EBIT TTM 141.8m / Avg Total Assets 643.7m |
| (D) 1.94 = Book Value of Equity 643.6m / Total Liabilities 331.7m |
| Total Rating: 10.46 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 79.29
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 3.36% = 1.68 |
| 3. FCF Margin 21.57% = 5.39 |
| 4. Debt/Equity 0.47 = 2.39 |
| 5. Debt/Ebitda 1.38 = 1.17 |
| 6. ROIC - WACC 18.84% = 12.50 |
| 7. RoE 24.19% = 2.02 |
| 8. Rev. Trend 43.60% = 2.18 |
| 9. Rev. CAGR 0.45% = 0.06 |
| 10. EPS Trend 22.99% = 0.57 |
| 11. EPS CAGR 3.36% = 0.34 |
What is the price of EXPO shares?
Over the past week, the price has changed by -1.92%, over one month by -0.83%, over three months by -7.00% and over the past year by -32.44%.
Is Exponent a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EXPO is around 60.85 USD . This means that EXPO is currently overvalued and has a potential downside of -13.13%.
Is EXPO a buy, sell or hold?
- Strong Buy: 1
- Buy: 0
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the EXPO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 88 | 25.6% |
| Analysts Target Price | 88 | 25.6% |
| ValueRay Target Price | 66.2 | -5.5% |
Last update: 2025-09-05 04:42
EXPO Fundamental Data Overview
CCE Cash And Equivalents = 231.8m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 36.1055
P/E Forward = 33.3333
P/S = 6.9971
P/B = 8.4917
P/EG = 3.14
Beta = 0.899
Revenue TTM = 560.5m USD
EBIT TTM = 141.8m USD
EBITDA TTM = 146.7m USD
Long Term Debt = 196.7m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 5.85m USD (from shortTermDebt, last quarter)
Debt = 202.5m USD (Calculated: Short Term 5.85m + Long Term 196.7m)
Net Debt = -151.5m USD (from netDebt column, last quarter)
Enterprise Value = 3.60b USD (3.63b + Debt 202.5m - CCE 231.8m)
Interest Coverage Ratio = unknown (Ebit TTM 141.8m / Interest Expense TTM 0.0)
FCF Yield = 3.36% (FCF TTM 120.9m / Enterprise Value 3.60b)
FCF Margin = 21.57% (FCF TTM 120.9m / Revenue TTM 560.5m)
Net Margin = 18.35% (Net Income TTM 102.8m / Revenue TTM 560.5m)
Gross Margin = 56.74% ((Revenue TTM 560.5m - Cost of Revenue TTM 242.5m) / Revenue TTM)
Tobins Q-Ratio = 5.60 (Enterprise Value 3.60b / Book Value Of Equity 643.6m)
Interest Expense / Debt = 3.17% (Interest Expense 6.42m / Debt 202.5m)
Taxrate = 26.04% (38.4m / 147.4m)
NOPAT = 104.9m (EBIT 141.8m * (1 - 26.04%))
Current Ratio = 3.15 (Total Current Assets 425.7m / Total Current Liabilities 135.0m)
Debt / Equity = 0.47 (Debt 202.5m / last Quarter total Stockholder Equity 427.8m)
Debt / EBITDA = 1.38 (Net Debt -151.5m / EBITDA 146.7m)
Debt / FCF = 1.67 (Debt 202.5m / FCF TTM 120.9m)
Total Stockholder Equity = 425.1m (last 4 quarters mean)
RoA = 17.78% (Net Income 102.8m, Total Assets 578.2m )
RoE = 24.19% (Net Income TTM 102.8m / Total Stockholder Equity 425.1m)
RoCE = 22.81% (Ebit 141.8m / (Equity 425.1m + L.T.Debt 196.7m))
RoIC = 24.68% (NOPAT 104.9m / Invested Capital 425.1m)
WACC = 5.84% (E(3.63b)/V(3.84b) * Re(6.03%)) + (D(202.5m)/V(3.84b) * Rd(3.17%) * (1-Tc(0.26)))
Shares Correlation 3-Years: -29.01 | Cagr: -0.07%
Discount Rate = 6.03% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 77.97% ; FCFE base≈130.3m ; Y1≈127.5m ; Y5≈129.6m
Fair Price DCF = 45.58 (DCF Value 2.30b / Shares Outstanding 50.5m; 5y FCF grow -3.13% → 3.0% )
Revenue Correlation: 43.60 | Revenue CAGR: 0.45%
Rev Growth-of-Growth: 0.67
EPS Correlation: 22.99 | EPS CAGR: 3.36%
EPS Growth-of-Growth: -4.23
Additional Sources for EXPO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle